" class="no-js "lang="en-US"> BPGbio Announces Focus on AI-Guided Breast Cancer Diagnostics
Monday, February 26, 2024

BPGbio Announces New Partnership with DoD Focused on AI-Guided Breast Cancer Diagnostics

BPGbio, a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that it will continue clinical validation of a novel breast cancer diagnostic panel that was developed under a previous agreement with the Department of Defense’s Clinical Breast Care Project (CBCP), including the DoD’s Uniformed Services University of the Health Sciences (USU), The Windber Research Institute, and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). The new panel, developed with AI, is designed to identify women who are diagnosed with ER+ breast cancer but do not respond to hormone therapy, so that more effective options could be offered to improve treatment response.

BPGbio’s Interrogative Biology® Platform will complete comprehensive omics analysis and assessment using tissue and plasma/serum samples from a CBCP-supported program focused on breast cancer research. The Interrogative Biology® Platform will also provide expanded assessment of BPGbio’s novel breast cancer diagnostic 34 gene panel with a focus on ER+ breast cancers, which are significantly on the rise.

“We are pleased to collaborate with BPGbio and use their AI and diagnostic platform to aid patients afflicted with breast cancer,” said Joseph Caravalho, Jr., M.D., HJF’s President and CEO. “The more treatment options offered earlier in the course of these diseases, the better the clinical outcomes will be. Breast cancer research is one of the many types of research that CBCP supports for those serving in uniform, and we know that innovations like BPGbio’s platforms may greatly advance both military and civilian medicine.”

The development of a novel diagnostic panel using AI as a non-invasive, non-PSA-based prostate cancer screening test began a few years ago. The diagnostic panel can distinguish prostate cancer from benign prostatic hyperplasia (BPH) individuals while also ruling out aggressive prostate cancers. This prevents the need for unnecessary biopsies in BPH men who inherently have elevated PSA. Now, a new panel will be used to screen breast cancer.

“We are honored to work with CBCP and use BPGbio’s Interrogative Biology® Platform to develop and validate another cancer diagnostic panel,” said Niven R. Narain, Ph.D., President and CEO of BPGbio. “The BPGbio team has exceptional expertise in translating comprehensive omics analysis into effective diagnostic products for various cancer indications, which improves the lives of the patients we serve.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more